MPs Caution UK Accords with Donald Trump are 'Unstable'.

Elected officials have expressed alarm that the United Kingdom's series of deals with Washington are "lacking a solid foundation." This follows revelations that a much-touted deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The deal on drug tariffs, promoted as a "landmark" achievement, remains an "agreement in principle" without a signed legal text. Observers point out that the official announcements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to increase medicine costs in return for only a pledge from President Trump," said David Henig, a trade policy analyst. "It is documented he has form for not following through on agreements."

Broader Instability and a Paused Tech Deal

Anxieties have been intensified by Washington's move to put on ice the high-value digital accord, which was previously described as "a transformative pact" in the bilateral relationship. The US pointed to a lack of progress from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions agreed to for British farmers as part of an initial accord have still not been formally signed off by the US, despite a looming January deadline. "It is our belief that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have admitted unease that the government's deals with Washington are lacking substance. One minister reportedly said the series of agreements as "resting on shaky ground," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's naive belief that his administration is a reliable partner. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Ministry sources have attempted to minimize the possibility of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that volatility is inherent in dealing with the Trump administration. However, they argue that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, issues have surfaced in enacting the broader trade deal. Promised reciprocal agricultural allowances have not materialized, and the assurance to "eliminate duties on UK metals" has is still pending, with tariffs staying at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.

Brian Hernandez
Brian Hernandez

A passionate writer and shopping enthusiast with a keen eye for quality products and lifestyle trends.